MedTrace Logo

Support of Colonization Resistance of the Gut Microbiota with the Synbiotic Food Supplement Nagasin®

NCT05800704 · Status: ACTIVE_NOT_RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 49

Last updated 2025-03-28

No results posted yet for this study

Summary

Double blind, placebo-controlled, parallel, multicentric trial to investigat whether Nagasin® can support the colonization resistance against C.difficile.

Conditions

  • C. Difficile Enteritis

Interventions

DIETARY_SUPPLEMENT

Nagasin

Lactobacillus, Lactococcus and Bifidobacteria strains with antimicrobial effect against C. difficile

DIETARY_SUPPLEMENT

maltodextrin

maltodextrin (placebo comparator)

Sponsors & Collaborators

  • Insel Gruppe AG, University Hospital Bern

    collaborator OTHER

  • Stadtspital Zürich

    collaborator OTHER

  • Kantonsspital Winterthur KSW

    collaborator OTHER

  • Luzerner Kantonsspital

    collaborator OTHER

  • Cantonal Hosptal, Baselland

    collaborator OTHER

  • University of Zurich

    lead OTHER

Principal Investigators

  • Isabelle M Frey-Wagner, PhD · University or Zurich, Institute of Medical Microbiology

Study Design

Allocation
RANDOMIZED
Purpose
OTHER
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
95 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-03-10
Primary Completion
2025-03-31
Completion
2025-03-31

Countries

  • Switzerland

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05800704 on ClinicalTrials.gov